AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18507596 — intervention group
Group type: COMPARATOR
Intervention: Nurse-determined humidity strategy
Number of subjects: 136
Study 16162753 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-based inspiratory muscle training (IMT) combined with breathing retraining (BR)
Number of subjects: 27
Study 14709187 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured (STR) intervention
Number of subjects: 40
Study 14709187 — intervention group
Group type: COMPARATOR
Intervention: Self-directed (SELF) intervention
Number of subjects: 40
Study 10648375 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body air displacement plethysmography
Number of subjects: 32
Study 10648375 — intervention group
Group type: COMPARATOR
Intervention: Hydrodensitometry
Number of subjects: 32
Study 9162604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs in patients with CHD and serum cholesterol >5.5 mmol I(‐1)
Number of subjects: 0
Study 9162604 — intervention group
Group type: EXPERIMENTAL
Intervention: Consider lipid-lowering drugs in patients without CHD when serum cholesterol exceeds 6.5 mmol I(‐1) and CHD risk >20% over the next 10 years
Number of subjects: 0
Study 9162604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary therapy aimed at decreasing fat intake, particularly saturated fat, and weight reduction in the obese
Number of subjects: 0
Study 9162604 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of glycaemic control in patients with raised lipids
Number of subjects: 0
Study 1899582 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (recombinant tissue plasminogen activator)
Number of subjects: 436
Study 1899582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 1899582 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 436
Study 6395938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (HCD)
Number of subjects: 24
Study 6395938 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine (1 percent)
Number of subjects: 24
Study 6395938 — intervention group
Group type: COMPARATOR
Intervention: Human allografts
Number of subjects: 24
Study 31545867 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual capsulorhexis
Number of subjects: 30
Study 31545867 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge vitrectorhexis
Number of subjects: 30
Study 29708630 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol 0.5% cream
Number of subjects: 38
Study 29708630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of diprospan combined with topical timolol 0.5% cream
Number of subjects: 38
Study 26079636 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with occupational therapy
Number of subjects: 15
Study 26079636 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with occupational therapy
Number of subjects: 15
Study 24763401 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment response assessed by leukemic blast counts in bone marrow on day 28 after first reinduction.
Number of subjects: 338
Study 24763401 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment response assessed by leukemic blast counts in bone marrow on day 15 after first reinduction.
Number of subjects: 338
Study 22736248 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental trial with breathing system clamping PET CO2 at 50 mmHg
Number of subjects: 9
Study 22736248 — intervention group
Group type: COMPARATOR
Intervention: Poikilocapnic control trial
Number of subjects: 9
Study 20370481 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 210
Study 20370481 — intervention group
Group type: COMPARATOR
Intervention: Delayed circumcision (Control)
Number of subjects: 210
Study 17109859 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Thermachoice III with ibuprofen 800 mg pre-treatment and nitrous oxide rescue analgesia
Number of subjects: 73
Study 17109859 — intervention group
Group type: COMPARATOR
Intervention: Daycase Thermachoice III with general anesthesia and fentanyl/diclofenac
Number of subjects: 73
Study 16331821 — intervention group
Group type: EXPERIMENTAL
Intervention: TCI remifentanil‐propofol (remifentanil at 6 microg/L and propofol at 3 mg/L)
Number of subjects: 60
Study 16331821 — intervention group
Group type: EXPERIMENTAL
Intervention: TCI remifentanil‐propofol
Number of subjects: 60
Study 16331821 — intervention group
Group type: COMPARATOR
Intervention: Control group (fentanyl 2.5 microg/kg and propofol 1‐2 mg/kg, maintained with fentanyl 0.03 microg.kg(‐1).min(‐1) and 1% isoflurane)
Number of subjects: 60
Study 16331821 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 16331821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 12082493 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate measurement after 5, 10, and 15 minutes in a sitting position
Number of subjects: 2230
Study 12082493 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 2230
Study 12082493 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Number of subjects: 2230
Study 9862539 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intramuscular stimulation
Number of subjects: 6
Study 9862539 — intervention group
Group type: COMPARATOR
Intervention: Surface stimulation
Number of subjects: 6
Study 7839545 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms (b.i.d.)
Number of subjects: 92
Study 7839545 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 400 micrograms (q.i.d.)
Number of subjects: 92
Study 2817074 — intervention group
Group type: EXPERIMENTAL
Intervention: Added-purpose occupational form (stirring cookie dough)
Number of subjects: 30
Study 2817074 — intervention group
Group type: COMPARATOR
Intervention: Rote exercise condition (no added purpose)
Number of subjects: 30
Study 788465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pervincamine
Number of subjects: 30
Study 788465 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 30973188 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 80
Study 30973188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg
Number of subjects: 80
Study 30973188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg
Number of subjects: 80
Study 30973188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 3 mg
Number of subjects: 80
Study 30973188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 80
Study 28665880 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV counselling and testing (HCT)
Number of subjects: 15456
Study 25308155 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional video
Number of subjects: 0
Study 25308155 — intervention group
Group type: EXPERIMENTAL
Intervention: Air cushion rim mask
Number of subjects: 0
Study 25308155 — intervention group
Group type: EXPERIMENTAL
Intervention: Round mask with two point top hold
Number of subjects: 0
Study 23082002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (150 mg/day orally) with FOLFOX or FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Number of subjects: 199
Study 23082002 — intervention group
Group type: COMPARATOR
Intervention: Placebo with FOLFOX or FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Number of subjects: 199
Study 23082002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 199
Study 16796300 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-set tests of spoken word recognition with highly confusable foils
Number of subjects: 0
Study 16796300 — intervention group
Group type: COMPARATOR
Intervention: Open-set tasks
Number of subjects: 0
Study 12564607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibenadet 400 microg
Number of subjects: 1573
Study 12564607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibenadet 600 microg
Number of subjects: 1573
Study 12564607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibenadet 1000 microg
Number of subjects: 1573
Study 12564607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibenadet 45 microg
Number of subjects: 1573
Study 12564607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibenadet 270 microg
Number of subjects: 1573
Study 12564607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibenadet 495 microg
Number of subjects: 1573
Study 12564607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1573
Study 12564607 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 microg
Number of subjects: 1573
Study 12564607 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 40 microg
Number of subjects: 1573
Study 10992168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin therapy
Number of subjects: 19
Study 8772731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Conventional Insulin Treatment (ICT)
Number of subjects: 59
Study 8772731 — intervention group
Group type: COMPARATOR
Intervention: Standard Insulin Treatment (ST)
Number of subjects: 59
Study 1595825 — intervention group
Group type: EXPERIMENTAL
Intervention: Remedial group (n = 22) received individual training with parquetry block assembly
Number of subjects: 45
Study 1595825 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive group (n = 23) received individual training in food preparation activities
Number of subjects: 45
Study 6529680 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg X kg‐1
Number of subjects: 40
Study 6529680 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg X kg‐1
Number of subjects: 40
Study 31801562 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 334
Study 31801562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 334
Study 31801562 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AL and DP
Number of subjects: 334
Study 28194841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment in HFpEF patients
Number of subjects: 187
Study 26464415 — intervention group
Group type: EXPERIMENTAL
Intervention: EA (Electroacupuncture at LI4)
Number of subjects: 12
Study 26464415 — intervention group
Group type: EXPERIMENTAL
Intervention: EA+LA (Electroacupuncture after injection of local anaesthetics)
Number of subjects: 12
Study 26464415 — intervention group
Group type: COMPARATOR
Intervention: EA+NB (Electroacupuncture after blockade of the brachial plexus)
Number of subjects: 12
Study 24263121 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.2-1 mg) during DSE
Number of subjects: 45
Study 24263121 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine without atropine (control group)
Number of subjects: 45
Study 21864414 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-social intervention consisting of 12 sessions of structured social support, problem solving techniques, group discussions, and trainer-supervised relaxation exercises (twice per week over six weeks)
Number of subjects: 0
Study 21864414 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-social intervention
Number of subjects: 0
Study 21864414 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 19212235 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded dental implants
Number of subjects: 12
Study 19212235 — intervention group
Group type: COMPARATOR
Intervention: Conventionally loaded dental implants
Number of subjects: 12
Study 17286529 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention
Number of subjects: 607
Study 17286529 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 607
Study 15109187 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg
Number of subjects: 75
Study 15109187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 75
Study 15109187 — intervention group
Group type: COMPARATOR
Intervention: Control (neither intervention)
Number of subjects: 75
Study 11555565 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aerosolized tobramycin solution for inhalation (TSI) administered twice daily for 4 weeks
Number of subjects: 74
Study 11555565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 11555565 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aerosolized tobramycin solution for inhalation (TSI)
Number of subjects: 74
Study 9683313 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention campaign of public and professional education during an 18-month intervention period.
Number of subjects: 600
Study 9683313 — intervention group
Group type: COMPARATOR
Intervention: Control communities (no intervention).
Number of subjects: 600
Study 8113547 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 43
Study 8113547 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 43
Study 8113547 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 43
Study 3183476 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilatation of the pouch and sphincter biofeedback training
Number of subjects: 40
Study 3183476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 31295717 — intervention group
Group type: EXPERIMENTAL
Intervention: MODAFINIL
Number of subjects: 36
Study 31295717 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 36
Study 28559456 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month, supervised and individually tailored modular multimodal exercise programme with spinal isometric training
Number of subjects: 40
Study 28559456 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 40
Study 26332527 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib plus dabrafenib
Number of subjects: 0
Study 26332527 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib
Number of subjects: 0
Study 23923408 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (10 mg) single morning dose
Number of subjects: 44
Study 23923408 — intervention group
Group type: COMPARATOR
Intervention: Mini pulse betamethasone (5 mg) single morning dose on 2 consecutive days
Number of subjects: 44
Study 21393112 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for 6 months
Number of subjects: 204
Study 21393112 — intervention group
Group type: COMPARATOR
Intervention: Partially breastfed
Number of subjects: 204
Study 21393112 — intervention group
Group type: COMPARATOR
Intervention: Non-breastfed
Number of subjects: 204
Study 21393112 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 204
Study 21393112 — intervention group
Group type: COMPARATOR
Intervention: Partially breastfed and non-breastfed
Number of subjects: 204
Study 19504119 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 19
Study 19504119 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 16515981 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA less than 1 ng/ml
Number of subjects: 30495
Study 16515981 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA 1.0 to 1.99 ng/ml
Number of subjects: 30495
Study 16515981 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA 2.0 to 2.99 ng/ml
Number of subjects: 30495
Study 16515981 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA 3.0 to 4.0 ng/ml
Number of subjects: 30495
Study 16515981 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with baseline PSA less than 1 ng/ml converting to PSA more than 4 ng/ml
Number of subjects: 30495
Study 16515981 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with baseline PSA less than 1 ng/ml and negative baseline DRE
Number of subjects: 30495
Study 15295729 — intervention group
Group type: EXPERIMENTAL
Intervention: AED1
Number of subjects: 64
Study 15295729 — intervention group
Group type: EXPERIMENTAL
Intervention: AED2
Number of subjects: 64
Study 15295729 — intervention group
Group type: EXPERIMENTAL
Intervention: AED3
Number of subjects: 64
Study 15295729 — intervention group
Group type: EXPERIMENTAL
Intervention: AED4
Number of subjects: 64
Study 15295729 — intervention group
Group type: COMPARATOR
Intervention: All AEDs
Number of subjects: 64
Study 10691220 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐6‐G 0.1 mg/kg
Number of subjects: 37
Study 10691220 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 37
Study 10691220 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg/kg
Number of subjects: 37
Study 9488217 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) at doses of 0.3, 1.0, and 3.0 microg/kg per min
Number of subjects: 20
Study 9488217 — intervention group
Group type: COMPARATOR
Intervention: Atropine at doses of 100 and 300 ng/kg per min
Number of subjects: 20
Study 8442923 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (tinidazole, thiabendazole, and cotrimoxazole)
Number of subjects: 28
Study 8442923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3510393 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (300 mg per week)
Number of subjects: 51
Study 3510393 — intervention group
Group type: COMPARATOR
Intervention: Control (no chloroquine)
Number of subjects: 51
Study 29914406 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies by general practitioners (GPs) during MUS consultations, including history-taking, physical examination (24.5%), additional investigations by the GP (11.1%), prescribing medication (24.6%), and providing explanations (11.2%).
Number of subjects: 77
Study 29914406 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies by GPs, including exploration of all complaint dimensions (3.5%), referral to a psychologist (0.5%), or psychiatrist (0.1%).
Number of subjects: 77
Study 29914406 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management of MUS by Dutch GPs.
Number of subjects: 77
Study 27513903 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone ophthalmoscopy
Number of subjects: 110
Study 27513903 — intervention group
Group type: COMPARATOR
Intervention: Slit-lamp biomicroscopy
Number of subjects: 110
Study 24919867 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible imputation strategy for missing data in SMARTs
Number of subjects: 0
Study 24919867 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from the Clinical Antipsychotic Trial of Intervention and Effectiveness
Number of subjects: 0
Study 22268960 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized e-health intervention (e-consultation, patient-tailored website, monitoring, and self-management training)
Number of subjects: 199
Study 22268960 — intervention group
Group type: COMPARATOR
Intervention: Usual face-to-face care (control group)
Number of subjects: 199
Study 22268960 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized e-health intervention
Number of subjects: 199
Study 20651386 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical loop electrosurgical excision procedure (LLETZ)
Number of subjects: 90
Study 20651386 — intervention group
Group type: COMPARATOR
Intervention: Prospective follow‐up without treatment
Number of subjects: 90
Study 18614918 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence measured through pill usage and questionnaire.
Number of subjects: 2957
Study 18614918 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete adherence (100% drug possession ratio).
Number of subjects: 2957
Study 18614918 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with adherence.
Number of subjects: 2957
Study 16212581 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF+EMD
Number of subjects: 15
Study 16212581 — intervention group
Group type: COMPARATOR
Intervention: CAF only
Number of subjects: 15
Study 12626218 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-cm² Estradot patch (50 micro g/day)
Number of subjects: 100
Study 12626218 — intervention group
Group type: COMPARATOR
Intervention: 12.5-cm² Climara patch
Number of subjects: 100
Study 12626218 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-cm² Estradot patch
Number of subjects: 100
Study 12626218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patches
Number of subjects: 100
Study 10652894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg) tablets administered twice daily
Number of subjects: 180
Study 10652894 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg) tablets administered thrice daily
Number of subjects: 180
Study 8908281 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternaria
Number of subjects: 0
Study 8908281 — intervention group
Group type: COMPARATOR
Intervention: Candida
Number of subjects: 0
Study 8908281 — intervention group
Group type: COMPARATOR
Intervention: Aspergillus
Number of subjects: 0
Study 1680885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 30 mg
Number of subjects: 11
Study 1680885 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 40 mg
Number of subjects: 11
Study 1680885 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 11
Study 6753711 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar V‐Y advancement
Number of subjects: 200
Study 6753711 — intervention group
Group type: COMPARATOR
Intervention: Cross‐finger flap
Number of subjects: 200
Study 6753711 — intervention group
Group type: COMPARATOR
Intervention: Simple dressing
Number of subjects: 200
Study 6753711 — intervention group
Group type: COMPARATOR
Intervention: Other methods (split skin grafting, full‐thickness skin grafting, Kutler's bilateral V‐Y advancement, revision amputation)
Number of subjects: 200
Study 31695864 — intervention group
Group type: EXPERIMENTAL
Intervention: MART (maintenance and reliever therapy)
Number of subjects: 1701
Study 31695864 — intervention group
Group type: COMPARATOR
Intervention: prn salbutamol
Number of subjects: 1701
Study 29193710 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine ointment
Number of subjects: 20
Study 29193710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20